PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jexpmedHomeThe Rockefeller University PressEditorsContactInstructions for AuthorsThis issue
 
J Exp Med. 1995 August 1; 182(2): 449–457.
PMCID: PMC2192113

Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor

Abstract

Considerable evidence has associated the expression of matrix metalloproteinases (MMPs) with the degradation of cartilage and bone in chronic conditions such as arthritis. Direct evaluation of MMPs' role in vivo has awaited the development of MMP inhibitors with appropriate pharmacological properties. We have identified butanediamide, N4- hydroxy-2-(2-methylpropyl)-N1-[2-[[2-(morpholinyl)ethyl]-,[S- (R*,S*)] (GI168) as a potent MMP inhibitor with sufficient solubility and stability to permit evaluation in an experimental model of chronic destructive arthritis (adjuvant-induced arthritis) in rats. In this model, pronounced acute and chronic synovial inflammation, distal tibia and metatarsal marrow hyperplasia associated with osteoclasia, severe bone and cartilage destruction, and ectopic new bone growth are well developed by 3 wk after adjuvant injection. Rats were injected with Freund's adjuvant on day 0. GI168 was was administered systemically from days 8 to 21 by osmotic minipumps implanted subcutaneously. GI168 at 6, 12, and 25 mg/kg per d reduced ankle swelling in a dose-related fashion. Radiological and histological ankle joint evaluation on day 22 revealed a profound dose related inhibition of bone and cartilage destruction in treated rats relative to rats receiving vehicle alone. A significant reduction in edema, pannus formation, periosteal new bone growth and the numbers of adherent marrow osteoclasts was also noted. However, no significant decrease in polymorphonuclear and mononuclear leukocyte infiltration of synovium and marrow hematopoietic cellularity was seen. This unique profile of antiarthritic activity indicates that GI168 is osteo- and chondro-protective, and it supports a direct role for MMP in cartilage and bone damage and pannus formation in adjuvant- induced arthritis.

Full Text

The Full Text of this article is available as a PDF (1.5M).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990 Apr;6(4):121–125. [PubMed]
  • Tetlow LC, Lees M, Ogata Y, Nagase H, Woolley DE. Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo. Rheumatol Int. 1993;13(2):53–59. [PubMed]
  • Sellers A, Meikle MC, Reynolds JJ. Collagenase and collagenase inhibitor levels following changes in bone resorption in vitro. Calcif Tissue Int. 1980;31(1):35–43. [PubMed]
  • Caputo CB, Sygowski LA, Wolanin DJ, Patton SP, Caccese RG, Shaw A, Roberts RA, DiPasquale G. Effect of synthetic metalloprotease inhibitors on cartilage autolysis in vitro. J Pharmacol Exp Ther. 1987 Feb;240(2):460–465. [PubMed]
  • Caputo CB, Sygowski LA, Patton SP, Wolanin DJ, Shaw A, Roberts RA, DiPasquale G. Protease inhibitors decrease rabbit cartilage degradation after meniscectomy. J Orthop Res. 1988;6(1):103–108. [PubMed]
  • Nixon JS, Bottomley KM, Broadhurst MJ, Brown PA, Johnson WH, Lawton G, Marley J, Sedgwick AD, Wilkinson SE. Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro. Int J Tissue React. 1991;13(5):237–241. [PubMed]
  • Mort JS, Dodge GR, Roughley PJ, Liu J, Finch SJ, DiPasquale G, Poole AR. Direct evidence for active metalloproteinases mediating matrix degradation in interleukin 1-stimulated human articular cartilage. Matrix. 1993 Mar;13(2):95–102. [PubMed]
  • Delaissé JM, Eeckhout Y, Sear C, Galloway A, McCullagh K, Vaes G. A new synthetic inhibitor of mammalian tissue collagenase inhibits bone resorption in culture. Biochem Biophys Res Commun. 1985 Dec 17;133(2):483–490. [PubMed]
  • Hasty KA, Reife RA, Kang AH, Stuart JM. The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum. 1990 Mar;33(3):388–397. [PubMed]
  • Wolfe GC, MacNaul KL, Buechel FF, McDonnell J, Hoerrner LA, Lark MW, Moore VL, Hutchinson NI. Differential in vivo expression of collagenase messenger RNA in synovium and cartilage. Quantitative comparison with stromelysin messenger RNA levels in human rheumatoid arthritis and osteoarthritis patients and in two animal models of acute inflammatory arthritis. Arthritis Rheum. 1993 Nov;36(11):1540–1547. [PubMed]
  • Zafarullah M, Pelletier JP, Cloutier JM, Martel-Pelletier J. Elevated metalloproteinase and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia. J Rheumatol. 1993 Apr;20(4):693–697. [PubMed]
  • Mohtai M, Smith RL, Schurman DJ, Tsuji Y, Torti FM, Hutchinson NI, Stetler-Stevenson WG, Goldberg GI. Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest. 1993 Jul;92(1):179–185. [PMC free article] [PubMed]
  • Case JP, Sano H, Lafyatis R, Remmers EF, Kumkumian GK, Wilder RL. Transin/stromelysin expression in the synovium of rats with experimental erosive arthritis. In situ localization and kinetics of expression of the transformation-associated metalloproteinase in euthymic and athymic Lewis rats. J Clin Invest. 1989 Dec;84(6):1731–1740. [PMC free article] [PubMed]
  • Burleigh MC, Barrett AJ, Lazarus GS. Cathepsin B1. A lysosomal enzyme that degrades native collagen. Biochem J. 1974 Feb;137(2):387–398. [PubMed]
  • Kirschke H, Kembhavi AA, Bohley P, Barrett AJ. Action of rat liver cathepsin L on collagen and other substrates. Biochem J. 1982 Feb 1;201(2):367–372. [PubMed]
  • Maciewicz RA, Etherington DJ. A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen. Biochem J. 1988 Dec 1;256(2):433–440. [PubMed]
  • Malone JD, Richards M, Jeffrey JJ. Recruitment of peripheral mononuclear cells by mammalian collagenase digests of type I collagen. Matrix. 1991 Aug;11(4):289–295. [PubMed]
  • Laskin DL, Kimura T, Sakakibara S, Riley DJ, Berg RA. Chemotactic activity of collagen-like polypeptides for human peripheral blood neutrophils. J Leukoc Biol. 1986 Mar;39(3):255–266. [PubMed]
  • Albini A, Adelmann-Grill BC. Collagenolytic cleavage products of collagen type I as chemoattractants for human dermal fibroblasts. Eur J Cell Biol. 1985 Jan;36(1):104–107. [PubMed]
  • Clark RA, Wikner NE, Doherty DE, Norris DA. Cryptic chemotactic activity of fibronectin for human monocytes resides in the 120-kDa fibroblastic cell-binding fragment. J Biol Chem. 1988 Aug 25;263(24):12115–12123. [PubMed]
  • Clark RL, Cuttino JT, Jr, Anderle SK, Cromartie WJ, Schwab JH. Radiologic analysis of arthritis in rats after systemic injection of streptococcal cell walls. Arthritis Rheum. 1979 Jan;22(1):25–35. [PubMed]
  • Bickett DM, Green MD, Berman J, Dezube M, Howe AS, Brown PJ, Roth JT, McGeehan GM. A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9). Anal Biochem. 1993 Jul;212(1):58–64. [PubMed]
  • Welgus HG, Grant GA, Sacchettini JC, Roswit WT, Jeffrey JJ. The gelatinolytic activity of rat uterus collagenase. J Biol Chem. 1985 Nov 5;260(25):13601–13606. [PubMed]
  • Weingarten H, Martin R, Feder J. Synthetic substrates of vertebrate collagenase. Biochemistry. 1985 Nov 5;24(23):6730–6734. [PubMed]
  • Billingham ME. Models of arthritis and the search for anti-arthritic drugs. Pharmacol Ther. 1983;21(3):389–428. [PubMed]
  • Vaes G, Delaissé JM, Eeckhout Y. Relative roles of collagenase and lysosomal cysteine-proteinases in bone resorption. Matrix Suppl. 1992;1:383–388. [PubMed]
  • Buttle DJ, Handley CJ, Ilic MZ, Saklatvala J, Murata M, Barrett AJ. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arthritis Rheum. 1993 Dec;36(12):1709–1717. [PubMed]
  • McGeehan GM, Becherer JD, Bast RC, Jr, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature. 1994 Aug 18;370(6490):558–561. [PubMed]
  • Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1105–1110. [PubMed]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press